Condition Directory

Head and Neck Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Head and Neck Cancer. Browse Head and Neck Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1257

Shown on this page

Current sort

How Head and Neck Cancer studies are organized in the registry

Most records use the formal phrase “squamous cell carcinoma of the head and neck” or the abbreviation HNSCC, and site-specific terms like “oropharyngeal” mark distinct subsets. HPV status is a common population-defining label in this portfolio, and combined-modality studies (radiation plus systemic therapy) are frequent.

Terms that often appear in related listings

HNSCC oropharyngeal HPV-positive chemoradiation

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 277–288 of 1,257 matching trials for Head and Neck Cancer.

Live ClinicalTrials.gov results.

Active filters: "HNSCC" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Tongue Cancer, Oral Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Interventions: Ultrasound imaging, Standard Treatment; Diagnostic Test · Other
Lead sponsor: Tobias Todsen; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Stanford, California • Atlanta, Georgia

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Neoplasms, Head Cancer, Throat Carcinoma
Interventions: Pembrolizumab, Carboplatin, Paclitaxel; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer, Human Papilloma Virus, Squamous Cell Carcinoma
Interventions: Lidocaine 1% Injectable Solution; Drug
Lead sponsor: Ryan Carey; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET); Drug · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Metformin Extended Release Oral Tablet, Pembrolizumab; Drug
Lead sponsor: Trisha Wise-Draper; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
Interventions: PF-08046032, Sasanlimab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: San Antonio, Texas • Seattle, Washington

Conditions: Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Interventions: Intra-op PET/CT Specimen Scanner; Device
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Oral Cancer, Chatbot, Patient Education, Prevention, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancers
Interventions: Traditional Education, AI-powered Chatbox; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
Interventions: Panitumumab, Zirconium Zr 89 Panitumumab, Positron Emission Tomography, Computed Tomography, Electronic Health Record Review; Biological · Drug · Procedure + 1 more
Lead sponsor: Eben Rosenthal; Other
Eligibility: 19 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: INBRX-106, Pembrolizumab; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 22 more

Conditions: Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Interventions: [68Ga]Ga-ABY-025; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Pancreatic Cancer, Liver Cancer
Interventions: YE-NEO-001; Biological
Lead sponsor: NantBioScience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: El Segundo, California

About this Head and Neck Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Head and Neck Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Head and Neck Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Head and Neck Cancer clinical trials

How Head and Neck Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

High-Resolution PET-CT Imaging for Surgical Margin Visualization

Enhancing Oral Cancer Awareness

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

About this Head and Neck Cancer clinical trials directory page